MaxCyte (MXCT) (MXCT)
:MXCT
Want to see MXCT full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.12Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced clear operational and strategic positives — including a strong cash position, meaningful OpEx reductions, a $3.0M SPL milestone in Q1, early product traction (ExPERT DTX and SeQure), and a $10M share repurchase authorization — against near-term commercial headwinds, notably a 25% decline in core revenue and weaker PA and license receipts driven by customer inventory management and discontinued programs. Management reiterated full-year guidance while taking a conservative stance on additional 2026 milestones; they emphasized stability in the late-stage cell and gene therapy market, confidence in the pipeline, and expectations for core revenue growth later in the year. Overall, the results reflect transitionary near-term pressure but solid financial flexibility and promising product/partner catalysts that could drive recovery and growth over the medium term.Company Guidance
Strong cash position and balance sheet
Ended Q1 2026 with $147.7M in cash and investments and no debt; company expects to end 2026 with at least $136M (excluding repurchases), providing financial flexibility for execution and the $10M share repurchase program authorized by the Board.
Significant operating expense reduction
Total operating expenses fell to $14.3M in Q1 2026 from $21.2M in Q1 2025, a reduction of ~$6.9M (~32.5%), reflecting restructuring and cost-efficiency actions implemented in 2025 and management's guidance that OpEx will remain near current levels (company expects ~ $60M OpEx for full-year 2026).
SPL milestones and royalty momentum
SPL program-related revenue was $3.4M in Q1 2026 (vs $2.1M in Q1 2025), including a $3.0M regulatory milestone tied to a customer that began dosing in a registrational study and $0.4M in royalty revenue — demonstrating tangible near-term SPL monetization.
Product launches and early traction (ExPERT DTX and SeQure)
Commercial launch of ExPERT DTX is progressing with early adoption across academic centers, biotech and large pharma and expected build in H2 2026; SeQure generated $0.6M revenue in Q1 2026 (reported as ~3x year-over-year growth from Q1 prior year) and is seeing new assay service agreements and customer engagement across ex‑vivo and in‑vivo programs.
Reaffirmed 2026 guidance
Management reiterated full-year 2026 revenue guidance of $30M–$32M (core revenue $25M–$27M and $5M SPL milestones & royalties), with core revenue expected to be weighted to the second half of the year.
Strong SPL partner pipeline and milestone opportunity
Company reports 29 SPL partners and 30+ programs in clinical and preclinical development; among 12 SPL programs currently in clinic the aggregate future pre-commercial milestone opportunity is ~ $100M and management highlighted five clinical programs with potential for near-term registrational/commercial milestones.
MXCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MXCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $0.82 | $1.02 | +24.09% |
Mar 24, 2026 | $0.74 | $0.69 | -6.89% |
Nov 12, 2025 | $1.58 | $1.51 | -4.43% |
Aug 06, 2025 | $2.04 | $1.43 | -29.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MaxCyte (MXCT) (MXCT) report earnings?
MaxCyte (MXCT) (MXCT) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
What is MaxCyte (MXCT) (MXCT) earnings time?
MaxCyte (MXCT) (MXCT) earnings time is at Aug 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MXCT EPS forecast?
MXCT EPS forecast for the fiscal quarter 2026 (Q2) is -0.09.